# Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

> **NCT00425477** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 26 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** bexarotene
- **GENETIC:** cytogenetic analysis
- **GENETIC:** fluorescence in situ hybridization
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00425477
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-09-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425477, "Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00425477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*